• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将非天然氨基酸引入 T 细胞表位以减轻肽特异性 T 细胞反应。

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses.

机构信息

Sanofi, Biologics Research, Vitry-sur-Seine, France.

Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.

出版信息

Front Immunol. 2021 Mar 11;12:637963. doi: 10.3389/fimmu.2021.637963. eCollection 2021.

DOI:10.3389/fimmu.2021.637963
PMID:33777029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7991740/
Abstract

Non-natural modifications are widely introduced into peptides to improve their therapeutic efficacy, but their impact on immunogenicity remains largely unknown. As the CD4 T-cell response is a key factor in triggering immunogenicity, we investigated the effect of introducing D-amino acids (Daa), amino isobutyric acid (Aib), N-methylation, C-methylation, reduced amide, and peptoid bonds into an immunoprevalent T-cell epitope on binding to a set of HLA-DR molecules, recognition, and priming of human T cells. Modifications are differentially accepted at multiple positions, but are all tolerated in the flanking regions. Introduction of Aib and Daa in the binding core had the most deleterious effect on binding to HLA-DR molecules and T-cell activation. Their introduction at the positions close to the P1 anchor residue abolished T-cell priming, suggesting they might be sufficient to dampen peptide immunogenicity. Other modifications led to variable effects on binding to HLA-DR molecules and T-cell reactivity, but none exhibited an increased ability to stimulate T cells. Altogether, non-natural modifications appear generally to diminish binding to HLA-DR molecules and hence T-cell stimulation. These data might guide the design of therapeutic peptides to make them less immunogenic.

摘要

非天然修饰广泛引入肽中以提高其治疗效果,但它们对免疫原性的影响在很大程度上仍不清楚。由于 CD4 T 细胞反应是引发免疫原性的关键因素,我们研究了在一组 HLA-DR 分子结合、识别和引发人类 T 细胞中引入 D-氨基酸 (Daa)、氨基异丁酸 (Aib)、N-甲基化、C-甲基化、还原酰胺和肽键对免疫流行 T 细胞表位的影响。修饰在多个位置被不同程度地接受,但在侧翼区域都被容忍。在结合核心中引入 Aib 和 Daa 对与 HLA-DR 分子的结合和 T 细胞激活的影响最为不利。在靠近 P1 锚定残基的位置引入它们会使 T 细胞启动失效,这表明它们可能足以抑制肽的免疫原性。其他修饰导致与 HLA-DR 分子结合和 T 细胞反应性的可变影响,但没有一种表现出增强刺激 T 细胞的能力。总的来说,非天然修饰似乎普遍降低了与 HLA-DR 分子的结合,从而降低了 T 细胞的刺激。这些数据可能有助于指导治疗性肽的设计,使其免疫原性降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/adc07ed5a10a/fimmu-12-637963-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/627c48c5e3f9/fimmu-12-637963-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/3065d7045480/fimmu-12-637963-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/d5e27b3e8b61/fimmu-12-637963-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/d72eaf3cd64f/fimmu-12-637963-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/adc07ed5a10a/fimmu-12-637963-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/627c48c5e3f9/fimmu-12-637963-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/3065d7045480/fimmu-12-637963-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/d5e27b3e8b61/fimmu-12-637963-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/d72eaf3cd64f/fimmu-12-637963-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/7991740/adc07ed5a10a/fimmu-12-637963-g0005.jpg

相似文献

1
Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses.将非天然氨基酸引入 T 细胞表位以减轻肽特异性 T 细胞反应。
Front Immunol. 2021 Mar 11;12:637963. doi: 10.3389/fimmu.2021.637963. eCollection 2021.
2
Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors.ANRS Lipo5 合成疫苗的 CD4 T 细胞表位层次结构依赖于健康供体中预先存在的肽特异性 T 细胞的频率。
J Immunol. 2013 Jun 1;190(11):5757-63. doi: 10.4049/jimmunol.1300145. Epub 2013 May 1.
3
Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.上皮癌抗原的人CD8和CD4 T细胞表位
Cancer Chemother Pharmacol. 2000;46 Suppl:S86-90. doi: 10.1007/pl00014057.
4
Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells.眼源性人疱疹病毒α交叉反应性 CD4 T 细胞的功能特征。
J Immunol. 2014 Apr 15;192(8):3730-9. doi: 10.4049/jimmunol.1302307. Epub 2014 Mar 12.
5
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.一种源自NY-ESO-1的表位,它能与多种HLA-DR和HLA-DP4分子发生混杂结合,并刺激来自表达NY-ESO-1的黑色素瘤患者的自体CD4+ T细胞。
J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751.
6
Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.丙型肝炎病毒NS3和核心蛋白混杂CD4 + T细胞表位的天然供体中T细胞启动的差异能力。
Eur J Immunol. 2007 Jun;37(6):1513-23. doi: 10.1002/eji.200636783.
7
The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.当用混杂肽生成功能性 HLA-DR 四聚体时,CD4+ T 细胞表位结合位是一个关键参数。
Eur J Immunol. 2010 Jun;40(6):1603-16. doi: 10.1002/eji.200940123.
8
In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.体外人CD4 + T细胞对痘苗保护性抗原B5R和A33R的反应。
Mol Immunol. 2009 Apr;46(7):1481-7. doi: 10.1016/j.molimm.2008.12.016. Epub 2009 Feb 3.
9
Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype.风疹衣壳蛋白表位的杂乱T细胞识别受共享HLA DR超型的DRB1*0403和DRB1*0901分子限制。
Hum Immunol. 1998 Mar;59(3):149-57. doi: 10.1016/s0198-8859(98)00006-8.
10
Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.通过CD4 + Th1/Th2淋巴细胞鉴定肿瘤相关抗原骆驼(CAMEL)的多个HLA - DR限制性表位。
J Immunol. 2004 Apr 15;172(8):5095-102. doi: 10.4049/jimmunol.172.8.5095.

引用本文的文献

1
Application and prospects of genetic engineering in CAR-NK cell therapy.基因工程在CAR-NK细胞疗法中的应用与前景
Front Immunol. 2025 May 23;16:1600411. doi: 10.3389/fimmu.2025.1600411. eCollection 2025.
2
Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy.治疗性肽:强化肽以提高疾病治疗效果的化学策略。
Amino Acids. 2025 May 8;57(1):25. doi: 10.1007/s00726-025-03454-5.
3
Homogeneous multi-payload antibody-drug conjugates.均一化多载物抗体药物偶联物。

本文引用的文献

1
Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes.埃博拉病毒核蛋白(NP)和糖蛋白(GP)的大规模图谱分析揭示了多个免疫优势且保守的CD4 T细胞表位。
Cell Mol Immunol. 2021 May;18(5):1323-1325. doi: 10.1038/s41423-020-0455-2. Epub 2020 May 12.
2
Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes.治疗性抗体可变区中的人类序列对CD4 T细胞表位定位的影响。
Cell Mol Immunol. 2020 Jun;17(6):656-658. doi: 10.1038/s41423-019-0304-3. Epub 2019 Oct 28.
3
Immunogenicity of Protein Pharmaceuticals.
Nat Chem. 2024 Jun;16(6):854-870. doi: 10.1038/s41557-024-01507-y. Epub 2024 May 17.
4
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics.T 细胞和 B 细胞表位分析用于抗体类药物的免疫原性评估和缓解。
MAbs. 2024 Jan-Dec;16(1):2324836. doi: 10.1080/19420862.2024.2324836. Epub 2024 Mar 21.
5
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.鉴定和免疫原性的根本原因pasotuxizumab(AMG 212),一个前列腺特异性膜抗原靶向双特异性 T 细胞接合器治疗。
Front Immunol. 2023 Oct 23;14:1261070. doi: 10.3389/fimmu.2023.1261070. eCollection 2023.
6
Recent advances in the development of therapeutic peptides.治疗性肽的最新进展。
Trends Pharmacol Sci. 2023 Jul;44(7):425-441. doi: 10.1016/j.tips.2023.04.003. Epub 2023 May 27.
7
A lysine-based 2:1-[α/aza]-pseudopeptide series used as additives in polymeric membranes for CO capture: synthesis, structural studies, and application.一种基于赖氨酸的2:1-[α/氮杂]-拟肽系列,用作聚合物膜中CO捕获的添加剂:合成、结构研究及应用。
RSC Adv. 2023 Mar 29;13(15):10051-10067. doi: 10.1039/d3ra00409k. eCollection 2023 Mar 27.
8
Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A Method Using Existing Algorithm Infrastructure and a Vision for Future Enhancements.含非天然氨基酸序列的免疫原性评估:一种利用现有算法框架的方法及对未来改进的展望。
Front Drug Discov (Lausanne). 2022;2. doi: 10.3389/fddsv.2022.952326. Epub 2022 Oct 10.
9
Differential T cell immune responses to deamidated adeno-associated virus vector.对脱酰胺化腺相关病毒载体的差异性T细胞免疫反应
Mol Ther Methods Clin Dev. 2022 Jan 18;24:255-267. doi: 10.1016/j.omtm.2022.01.005. eCollection 2022 Mar 10.
蛋白质类药物的免疫原性。
J Pharm Sci. 2019 May;108(5):1637-1654. doi: 10.1016/j.xphs.2018.12.014. Epub 2018 Dec 30.
4
THPdb: Database of FDA-approved peptide and protein therapeutics.THPdb:美国食品药品监督管理局批准的肽类和蛋白质疗法数据库。
PLoS One. 2017 Jul 31;12(7):e0181748. doi: 10.1371/journal.pone.0181748. eCollection 2017.
5
Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.从健康供体中鉴定出的英夫利昔单抗和利妥昔单抗的CD4 T细胞表位的特性分析
Front Immunol. 2017 May 5;8:500. doi: 10.3389/fimmu.2017.00500. eCollection 2017.
6
The immune epitope database (IEDB) 3.0.免疫表位数据库(IEDB)3.0
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12. doi: 10.1093/nar/gku938. Epub 2014 Oct 9.
7
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.蛋白类治疗药物的 T 细胞依赖性免疫原性:临床前评估与缓解策略
Clin Immunol. 2013 Dec;149(3):534-55. doi: 10.1016/j.clim.2013.09.006. Epub 2013 Sep 25.
8
NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.NetMHCIIpan-3.0 是一种常见的 pan-specific MHC 类 II 预测方法,包括所有三种人类 MHC 类 II 同种异型,HLA-DR、HLA-DP 和 HLA-DQ。
Immunogenetics. 2013 Oct;65(10):711-24. doi: 10.1007/s00251-013-0720-y. Epub 2013 Jul 31.
9
Hierarchy of CD4 T cell epitopes of the ANRS Lipo5 synthetic vaccine relies on the frequencies of pre-existing peptide-specific T cells in healthy donors.ANRS Lipo5 合成疫苗的 CD4 T 细胞表位层次结构依赖于健康供体中预先存在的肽特异性 T 细胞的频率。
J Immunol. 2013 Jun 1;190(11):5757-63. doi: 10.4049/jimmunol.1300145. Epub 2013 May 1.
10
Peptides as therapeutics with enhanced bioactivity.肽类作为具有增强生物活性的治疗药物。
Curr Med Chem. 2012;19(26):4451-61. doi: 10.2174/092986712803251548.